Is NCT07347405 recruiting in Tucson, AZ?

Yes, NCT07347405 is currently recruiting participants at its Tucson, AZ location. This obsessive-compulsive disorder clinical trial is actively enrolling qualified participants.

How do I join the obsessive-compulsive disorder clinical trial in Tucson?

To join this clinical trial in Tucson, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Tucson clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Obsessive-Compulsive Disorder Clinical Trial in Tucson, AZ

About This Obsessive-Compulsive Disorder Study in Tucson

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Sponsor: Francisco A Moreno

Who Can Participate

Inclusion Criteria

Aged 18 years old, and older

Have OCD (DSM-5) based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).

At least moderate severity: Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥16.

Failed at least one adequate trial of guideline concordant treatment.

Considered safe for independent living

Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:

Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors

Other active OCD treatments (cognitive behavioral therapy \[CBT\] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications) \

Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.

5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin

Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks

Exclusion Criteria

Concurrent active substance use disorder, or a personal history of psychosis.

History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS)32

Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion. Examples include: 1) Cardiovascular conditions: lifetime history of stroke, lifetime myocardial infarction, uncontrolled hypertension (resting blood pressure \>140/90 mmHg), tachycardia (resting heart rate \>100 beats per minute), elongated QT interval corrected by Fridericia's formula (QTcF; interval \>450 msec), participants with existing valvular heart disease, or clinically significant arrhythmia (\<1 year prior to signing the ICF); 2) Metabolic conditions: subjects with diabetes should have a stable diabetes treatment regimen and no history of diabetic ketoacidosis, hyperglycemic coma, or no hypoglycemic episodes with glucose below 54 mg/dL in the 3 months prior to baseline, and fasting glucose \>70 mg/dL at baseline; 3) Severe renal impairment: eGFR \<45 mL/min/1.73 m²); and Liver failure: Child-Pugh Classes B and C.

Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea

Clinically significant renal or hepatic impairment, per clinical judgment of a study physician

EKG QTc ≥ 450 msec

Psychiatric comorbidity that may represent an acute risk to their own or other's safety, including history of bipolar disorder (I or II) in the participant or first degree relative, as well as any family history of psychosis.

Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.

Participants who are pregnant, breastfeeding, planning a pregnancy, or planning to donate sperm within three months post-last study drug administration.

Participants of childbearing potential or participants with partners of childbearing potential who engage in intercourse which could result in pregnancy are unwilling/unable to practice medically acceptable highly effective birth control (double barrier, oral and injectable pharmacological contraceptives, or surgical such as vasectomy or bilateral tubal occlusion) during the study and up to three months after the last study drug administration.

Suicide attempt within the 12 months prior to enrollment

Any condition for which MRI is contraindicated, at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.

Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:

Cannabinoids (marijuana, synthetic cannabinoids)

Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)

Opioids (natural and synthetic),

Sedatives (benzodiazepines, barbiturates, GHB, zolpidem, zaleplon, zopiclone)

Hallucinogens (DMT, ibogaine, LSD, MDMA, psilocybin, psilocin, PSP)

Weight below 45kg

Allergy or significant intolerance to chocolate or cocoa

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT07347405) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obsessive-Compulsive Disorder Treatment Options in Tucson, AZ

If you're searching for obsessive-compulsive disorder treatment options in Tucson, AZ, this clinical trial (NCT07347405) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced obsessive-compulsive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obsessive-compulsive disorder clinical trials near you to find additional studies recruiting in your area.

Obsessive-Compulsive Disorder Clinical Trial in Tucson, AZ

Expert Care in Tucson

IRB Approved

No-Cost Care

Apply for This Tucson Location

Why Participate?

Simple Process